Tegaserod

Tegaserod
Clinical data
Trade namesZelnorm, Zelmac
AHFS/Drugs.comMonograph
Pregnancy
category
  • AU: B3
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • US: Usage requires authorization from the FDA
Pharmacokinetic data
Bioavailability10%
Protein binding98%
MetabolismGastric and hepatic
Elimination half-life11 ± 5 hours
ExcretionFecal and renal
Identifiers
  • (2E)-2-[(5-Methoxy-1H-indol-3-yl)methylene]-N-pentylhydrazinecarboximidamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.158.793 Edit this at Wikidata
Chemical and physical data
FormulaC16H23N5O
Molar mass301.394 g·mol−1
3D model (JSmol)
  • CCCCCNC(=N)NN=Cc1c[nH]c2ccc(OC)cc12
  • InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+ checkY
  • Key:IKBKZGMPCYNSLU-RGVLZGJSSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation.[1] Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects. Before then, it was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating, and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation.[2]

  1. ^ "New Data for Zelnorm". Archived from the original on December 9, 2007. Retrieved March 30, 2007.
  2. ^ "FDA approves first treatment for women with irritable-bowel syndrome". Food and Drug Administration. Archived from the original on February 5, 2007. Retrieved March 30, 2007.